Combined Use of Factor VII Polypeptides and Factor VIII Polypeptides
AssigneeNovo Nordisk HealthCare A/G
InventorsJens Knudsen, Ulla Hedner, Rasmus Rojkjaer
Life of this patent
Estimating the term…
Abstract
The invention concerns a pharmaceutical preparation comprising a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide. The invention also concerns use of a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide for manufacture of a medicament for pharmaceutical use as well as methods for prevention or treatment of bleeding episodes in subjects.
Claims30
A pharmaceutical composition comprising (i) a preparation of factor VII or a factor VII-related polypeptide, and (ii) a preparation of human factor VIII or a human factor VIII-related polypeptide, wherein (a) the amount of factor VII or factor VII-related polypeptide and factor VIII or factor VIII-related polypeptide in the composition is sufficient to treat bleedings and (b) the factor VII or factor VII-related polypeptide and the human factor VIII or human factor VIII-related polypeptide are the sole hemostatic agents in the composition.
A kit of parts for treatment of bleeding episodes comprising:
- (i) a pharmaceutical composition, wherein said composition comprises:
- (a) a first amount of a preparation of a factor VII or factor VII-related polypeptide and a pharmaceutically acceptable carrier in a first unit dosage form;
- (b) a second amount of a preparation of a factor VIII or factor VIII-related polypeptide and a pharmaceutically acceptable carrier in a second unit dosage form;
- and (ii) a container, wherein the first and second amounts together are effective to treat a bleeding episode and the factor VII or factor VII-related polypeptide and the factor VIII or factor VIII-related polypeptide are the sole hemostatic agents contained in the kit.
A method for treating bleeding episodes in a subject comprising administering to a subject in need thereof a pharmaceutical composition comprising:
- a first amount of a preparation of a factor VII or factor VII-related polypeptide and a second amount of a preparation of a factor VIII or factor VIII-related polypeptide, wherein the first and second amounts together are effective to treat bleedings, and wherein the factor VII or factor VII-related polypeptide and the factor VIII or factor VIII-related polypeptide are the sole hemostatic agents administered to the subject.
A method to enhance haemostasis in a subject comprising administering to a subject in need thereof a pharmaceutical composition comprising:
- a first amount of a preparation of a factor VII or factor VII-related polypeptide and a second amount of a preparation of a factor VIII or factor VIII-related polypeptide, wherein the first and second amounts together are effective to enhance haemostasis and wherein the factor VII or factor VII-related polypeptide and factor VIII or factor VIII-related polypeptide are the sole hemostatic agents administered to the subject.
A kit containing a treatment for bleeding episodes comprising (a) a first amount of a factor VII or factor VII-related polypeptide and a second amount of a factor VIII or factor VIII-related polypeptide and a pharmaceutically acceptable carrier in a one-unit dosage form and (b) a container, wherein said first and second amounts together are effective to treat bleeding episodes and the factor VII or factor VII-related polypeptide and the factor VIII or factor VIII-related polypeptide are the sole hemostatic agents contained in the kit.
Dependencies are inferred from the claim text.